{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:29:07Z","timestamp":1792092547912,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T00:00:00Z","timestamp":1752278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010677","name":"H2020 Health","doi-asserted-by":"publisher","award":["115797"],"award-info":[{"award-number":["115797"]}],"id":[{"id":"10.13039\/100010677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C1\/18\/006"],"award-info":[{"award-number":["C1\/18\/006"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["C16\/24\/012"],"award-info":[{"award-number":["C16\/24\/012"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004040","name":"KU Leuven","doi-asserted-by":"publisher","award":["KA\/20\/077"],"award-info":[{"award-number":["KA\/20\/077"]}],"id":[{"id":"10.13039\/501100004040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00125-025-06490-8","type":"journal-article","created":{"date-parts":[[2025,7,12]],"date-time":"2025-07-12T08:45:08Z","timestamp":1752309908000},"page":"2263-2276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Verapamil and low-dose anti-mouse thymocyte globulin combination therapy stably reverses recent-onset type 1 diabetes in NOD mice by acting on the beta cell and immune axes"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7310-6103","authenticated-orcid":false,"given":"Laure","family":"Degroote","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3133-7507","authenticated-orcid":false,"given":"Pieter-Jan","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Viaene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-974X","authenticated-orcid":false,"given":"Yves","family":"Heremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunter","family":"Leuckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Geukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0542-5708","authenticated-orcid":false,"given":"Nico","family":"De Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8259-3329","authenticated-orcid":false,"given":"Willem","family":"Staels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4055-5233","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3559-6089","authenticated-orcid":false,"given":"Conny","family":"Gysemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,12]]},"reference":[{"issue":"10","key":"6490_CR1","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2337\/dc22-0308","volume":"45","author":"RL Anderson","year":"2022","unstructured":"Anderson RL, DiMeglio LA, Mander AP et al (2022) Innovative designs and logistical considerations for expedited clinical development of combination disease-modifying treatments for type 1 diabetes. Diabetes Care 45(10):2189\u20132201. https:\/\/doi.org\/10.2337\/dc22-0308","journal-title":"Diabetes Care"},{"issue":"4","key":"6490_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.20517\/mtod.2022.16","volume":"2","author":"C Mathieu","year":"2022","unstructured":"Mathieu C, Martens P-J (2022) Arresting type 1 diabetes: are we there yet? Obstacles and opportunities. Metab Target Organ Damage 2(4):15. https:\/\/doi.org\/10.20517\/mtod.2022.16","journal-title":"Metab Target Organ Damage"},{"issue":"5","key":"6490_CR3","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00125-021-05398-3","volume":"64","author":"BJ von Scholten","year":"2021","unstructured":"von Scholten BJ, Kreiner FF, Gough SCL, von Herrath M (2021) Current and future therapies for type 1 diabetes. Diabetologia 64(5):1037\u20131048. https:\/\/doi.org\/10.1007\/s00125-021-05398-3","journal-title":"Diabetologia"},{"issue":"11","key":"6490_CR4","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.tem.2024.03.006","volume":"35","author":"S Bourgeois","year":"2024","unstructured":"Bourgeois S, Coenen S, Degroote L et al (2024) Harnessing beta cell regeneration biology for diabetes therapy. Trends Endocrinol Metab 35(11):951\u2013966. https:\/\/doi.org\/10.1016\/j.tem.2024.03.006","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"6490_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s41591-018-0089-4","volume":"24","author":"F Ovalle","year":"2018","unstructured":"Ovalle F, Grimes T, Xu G et al (2018) Verapamil and beta cell function in adults with recent-onset type 1 diabetes. Nat Med 24(8):1108\u20131112. https:\/\/doi.org\/10.1038\/s41591-018-0089-4","journal-title":"Nat Med"},{"issue":"12","key":"6490_CR6","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jama.2023.2064","volume":"329","author":"GP Forlenza","year":"2023","unstructured":"Forlenza GP, McVean J, Beck RW et al (2023) Effect of verapamil on pancreatic beta cell function in newly diagnosed pediatric type 1 diabetes: a randomized clinical trial. JAMA 329(12):990\u2013999. https:\/\/doi.org\/10.1001\/jama.2023.2064","journal-title":"JAMA"},{"issue":"8","key":"6490_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/antiox9080765","volume":"9","author":"E Yoshihara","year":"2020","unstructured":"Yoshihara E (2020) TXNIP\/TBP-2: a master regulator for glucose homeostasis. Antioxidants (Basel) 9(8):765. https:\/\/doi.org\/10.3390\/antiox9080765","journal-title":"Antioxidants (Basel)"},{"issue":"4","key":"6490_CR8","doi-asserted-by":"publisher","first-page":"848","DOI":"10.2337\/db11-0955","volume":"61","author":"G Xu","year":"2012","unstructured":"Xu G, Chen J, Jing G, Shalev A (2012) Preventing \u03b2-cell loss and diabetes with calcium channel blockers. Diabetes 61(4):848\u2013856. https:\/\/doi.org\/10.2337\/db11-0955","journal-title":"Diabetes"},{"issue":"7","key":"6490_CR9","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1038\/s12276-023-01019-8","volume":"55","author":"EH Choi","year":"2023","unstructured":"Choi EH, Park SJ (2023) TXNIP: a key protein in the cellular stress response pathway and a potential therapeutic target. Exp Mol Med 55(7):1348\u20131356. https:\/\/doi.org\/10.1038\/s12276-023-01019-8","journal-title":"Exp Mol Med"},{"issue":"5","key":"6490_CR10","doi-asserted-by":"publisher","first-page":"E1133","DOI":"10.1152\/ajpendo.90944.2008","volume":"296","author":"J Chen","year":"2009","unstructured":"Chen J, Cha-Molstad H, Szabo A, Shalev A (2009) Diabetes induces and calcium channel blockers prevent cardiac expression of pro-apoptotic thioredoxin-interacting protein. Am J Physiol Endocrinol Metab 296(5):E1133\u2013E1139. https:\/\/doi.org\/10.1152\/ajpendo.90944.2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"3","key":"6490_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.bbrc.2005.08.161","volume":"336","author":"AH Minn","year":"2005","unstructured":"Minn AH, Pise-Masison CA, Radonovich M et al (2005) Gene expression profiling in INS-1 cells overexpressing thioredoxin-interacting protein. Biochem Biophys Res Commun 336(3):770\u2013778. https:\/\/doi.org\/10.1016\/j.bbrc.2005.08.161","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"6490_CR12","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1074\/jbc.M109.034421","volume":"285","author":"G Saxena","year":"2010","unstructured":"Saxena G, Chen J, Shalev A (2010) Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. J Biol Chem 285(6):3997\u20134005. https:\/\/doi.org\/10.1074\/jbc.M109.034421","journal-title":"J Biol Chem"},{"issue":"5","key":"6490_CR13","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/me.2014-1041","volume":"28","author":"J Chen","year":"2014","unstructured":"Chen J, Jing G, Xu G, Shalev A (2014) Thioredoxin-interacting protein stimulates its own expression via a positive feedback loop. Mol Endocrinol 28(5):674\u2013680. https:\/\/doi.org\/10.1210\/me.2014-1041","journal-title":"Mol Endocrinol"},{"issue":"7","key":"6490_CR14","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0192-0561(94)90102-3","volume":"16","author":"B Zanker","year":"1994","unstructured":"Zanker B, Marx S, Strom TB, K\u00f6hler H (1994) The immunosuppressive effects of verapamil upon mitogen activated and allo-antigen inducible human cytotoxic T-lymphocytes. Int J Immunopharmacol 16(7):507\u2013517. https:\/\/doi.org\/10.1016\/0192-0561(94)90102-3","journal-title":"Int J Immunopharmacol"},{"issue":"4","key":"6490_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/archfami.4.4.368","volume":"4","author":"NW Tietz","year":"1995","unstructured":"Tietz NW, Thompson J (1995) Possible concentration-dependent suppression of immune response by verapamil. Arch Fam Med 4(4):368\u2013369. https:\/\/doi.org\/10.1001\/archfami.4.4.368","journal-title":"Arch Fam Med"},{"issue":"4","key":"6490_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/00007890-200002270-00021","volume":"69","author":"RA Blaheta","year":"2000","unstructured":"Blaheta RA, Hailer NP, Brude N et al (2000) In vitro analysis of verapamil-induced immunosuppression: potent inhibition of T cell motility and lymphocytic transmigration through allogeneic endothelial cells. Transplantation 69(4):588\u2013597. https:\/\/doi.org\/10.1097\/00007890-200002270-00021","journal-title":"Transplantation"},{"issue":"7","key":"6490_CR17","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.3390\/pharmaceutics14071478","volume":"14","author":"JI Veytia-Bucheli","year":"2022","unstructured":"Veytia-Bucheli JI, Alvarado-Vel\u00e1zquez DA, Possani LD, Gonz\u00e1lez-Amaro R, Rosenstein Y (2022) The Ca2+ channel blocker verapamil inhibits the in vitro activation and function of T lymphocytes: a 2022 reappraisal. Pharmaceutics 14(7):1478. https:\/\/doi.org\/10.3390\/pharmaceutics14071478","journal-title":"Pharmaceutics"},{"issue":"1","key":"6490_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1038\/s41467-022-28826-3","volume":"13","author":"G Xu","year":"2022","unstructured":"Xu G, Grimes TD, Grayson TB et al (2022) Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes. Nat Commun 13(1):1159. https:\/\/doi.org\/10.1038\/s41467-022-28826-3","journal-title":"Nat Commun"},{"issue":"1","key":"6490_CR19","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1172\/JCI76238","volume":"125","author":"R Kenefeck","year":"2015","unstructured":"Kenefeck R, Wang CJ, Kapadi T et al (2015) Follicular helper T cell signature in type 1 diabetes. J Clin Invest 125(1):292\u2013303. https:\/\/doi.org\/10.1172\/JCI76238","journal-title":"J Clin Invest"},{"issue":"4","key":"6490_CR20","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00125-015-3509-8","volume":"58","author":"RC Ferreira","year":"2015","unstructured":"Ferreira RC, Simons HZ, Thompson WS et al (2015) IL-21 production by CD4+ effector T cells and frequency of circulating follicular helper T cells are increased in type 1 diabetes patients. Diabetologia 58(4):781\u2013790. https:\/\/doi.org\/10.1007\/s00125-015-3509-8","journal-title":"Diabetologia"},{"issue":"1","key":"6490_CR21","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1096\/fj.201901637R","volume":"34","author":"F Shao","year":"2020","unstructured":"Shao F, Zheng P, Yu D, Zhou Z, Jia L (2020) Follicular helper T cells in type 1 diabetes. FASEB J 34(1):30\u201340. https:\/\/doi.org\/10.1096\/fj.201901637R","journal-title":"FASEB J"},{"issue":"7","key":"6490_CR22","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","volume":"21","author":"M Mohty","year":"2007","unstructured":"Mohty M (2007) Mechanisms of action of anti-thymocyte globulin: T-cell depletion and beyond. Leukemia 21(7):1387\u20131394. https:\/\/doi.org\/10.1038\/sj.leu.2404683","journal-title":"Leukemia"},{"issue":"9","key":"6490_CR23","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.2337\/dc18-0494","volume":"41","author":"MJ Haller","year":"2018","unstructured":"Haller MJ, Schatz DA, Skyler JS et al (2018) Low-dose anti-thymocyte globulin (ATG) preserves \u03b2-cell function and improves HbA1c in new-onset type 1 diabetes. Diabetes Care 41(9):1917\u20131925. https:\/\/doi.org\/10.2337\/dc18-0494","journal-title":"Diabetes Care"},{"issue":"6","key":"6490_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2337\/db19-0057","volume":"68","author":"MJ Haller","year":"2019","unstructured":"Haller MJ, Long SA, Blanchfield JL et al (2019) Low-dose anti-thymocyte globulin preserves C-peptide, reduces HbA1c, and increases regulatory to conventional T-cell ratios in new-onset type 1 diabetes: Two-year clinical trial data. Diabetes 68(6):1267\u20131276. https:\/\/doi.org\/10.2337\/db19-0057","journal-title":"Diabetes"},{"issue":"16","key":"6490_CR25","doi-asserted-by":"publisher","first-page":"E161812","DOI":"10.1172\/jci.insight.161812","volume":"8","author":"LM Jacobsen","year":"2023","unstructured":"Jacobsen LM, Diggins K, Blanchfield L et al (2023) Responders to low-dose ATG induce CD4+ T cell exhaustion in type 1 diabetes. JCI Insight 8(16):E161812. https:\/\/doi.org\/10.1172\/jci.insight.161812","journal-title":"JCI Insight"},{"issue":"12","key":"6490_CR26","doi-asserted-by":"publisher","first-page":"e053669","DOI":"10.1136\/bmjopen-2021-053669","volume":"11","author":"CS Wilhelm-Benartzi","year":"2021","unstructured":"Wilhelm-Benartzi CS, Miller SE, Bruggraber S et al (2021) Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. BMJ Open 11(12):e053669. https:\/\/doi.org\/10.1136\/bmjopen-2021-053669","journal-title":"BMJ Open"},{"issue":"3","key":"6490_CR27","doi-asserted-by":"publisher","first-page":"e0173088","DOI":"10.1371\/journal.pone.0173088","volume":"12","author":"M Buszko","year":"2017","unstructured":"Buszko M, Cardini B, Oberhuber R et al (2017) Differential depletion of total T cells and regulatory T cells and prolonged allotransplant survival in CD3\u0190 humanized mice treated with polyclonal anti human thymocyte globulin. PLoS One 12(3):e0173088. https:\/\/doi.org\/10.1371\/journal.pone.0173088","journal-title":"PLoS One"},{"issue":"2","key":"6490_CR28","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2337\/db06-1384","volume":"57","author":"G Simon","year":"2008","unstructured":"Simon G, Parker M, Ramiya V et al (2008) Murine anti-thymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. Diabetes 57(2):405\u2013414. https:\/\/doi.org\/10.2337\/db06-1384","journal-title":"Diabetes"},{"issue":"1","key":"6490_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13578-023-01110-7","volume":"13","author":"F Sun","year":"2023","unstructured":"Sun F, Yang CL, Wang FX et al (2023) Pancreatic draining lymph nodes (PLNs) serve as a pathogenic hub contributing to the development of type 1 diabetes. Cell Biosci 13(1):156. https:\/\/doi.org\/10.1186\/s13578-023-01110-7","journal-title":"Cell Biosci"},{"issue":"5","key":"6490_CR30","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1210\/en.2004-1378","volume":"146","author":"AH Minn","year":"2005","unstructured":"Minn AH, Hafele C, Shalev A (2005) Thioredoxin-interacting protein is stimulated by glucose through a carbohydrate response element and induces \u03b2-cell apoptosis. Endocrinology 146(5):2397\u20132405. https:\/\/doi.org\/10.1210\/en.2004-1378","journal-title":"Endocrinology"},{"issue":"10","key":"6490_CR31","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.2337\/db23-0256","volume":"72","author":"G Xu","year":"2023","unstructured":"Xu G, Chen J, Lu B, Sethupathy P, Qian WJ, Shalev A (2023) Verapamil prevents decline of IGF-I in subjects with type 1 diabetes and promotes \u03b2-cell IGF-I signaling. Diabetes 72(10):1460\u20131469. https:\/\/doi.org\/10.2337\/db23-0256","journal-title":"Diabetes"},{"issue":"2","key":"6490_CR32","doi-asserted-by":"publisher","first-page":"195","DOI":"10.2337\/dc12-0836","volume":"36","author":"REJ Besser","year":"2013","unstructured":"Besser REJ, Shields BM, Casas R, Hattersley AT, Ludvigsson J (2013) Lessons from the mixed-meal tolerance test: use of 90-minute and fasting C-peptide in pediatric diabetes. Diabetes Care 36(2):195\u2013201. https:\/\/doi.org\/10.2337\/dc12-0836","journal-title":"Diabetes Care"},{"key":"6490_CR33","doi-asserted-by":"publisher","first-page":"1322148","DOI":"10.3389\/fphar.2023.1322148","volume":"14","author":"H Arefanian","year":"2023","unstructured":"Arefanian H, Koti L, Sindhu S, Ahmad R, Al Madhoun A, Al-Mulla F (2023) Verapamil chronicles: advances from cardiovascular to pancreatic \u03b2-cell protection. Front Pharmacol 14:1322148. https:\/\/doi.org\/10.3389\/fphar.2023.1322148","journal-title":"Front Pharmacol"},{"issue":"9","key":"6490_CR34","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1210\/en.2002-220564","volume":"143","author":"A Shalev","year":"2002","unstructured":"Shalev A, Pise-Masison CA, Radonovich M et al (2002) Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGF-\u03b2 signaling pathway. Endocrinology 143(9):3695\u20133698. https:\/\/doi.org\/10.1210\/en.2002-220564","journal-title":"Endocrinology"},{"issue":"16","key":"6490_CR35","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.3390\/ijms20163969","volume":"20","author":"M Coucha","year":"2019","unstructured":"Coucha M, Shanab AY, Sayed M, Vazdarjanova A, El-Remessy AB (2019) Modulating expression of thioredoxin interacting protein (TXNIP) prevents secondary damage and preserves visual function in a mouse model of ischemia\/reperfusion. Int J Mol Sci 20(16):3969. https:\/\/doi.org\/10.3390\/ijms20163969","journal-title":"Int J Mol Sci"},{"issue":"4","key":"6490_CR36","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2337\/db07-0715","volume":"57","author":"J Chen","year":"2008","unstructured":"Chen J, Saxena G, Mungrue IN, Lusis AJ, Shalev A (2008) Thioredoxin-interacting protein: a critical link between glucose toxicity and \u03b2-cell apoptosis. Diabetes 57(4):938\u2013944. https:\/\/doi.org\/10.2337\/db07-0715","journal-title":"Diabetes"},{"issue":"8","key":"6490_CR37","doi-asserted-by":"publisher","first-page":"e0255405","DOI":"10.1371\/journal.pone.0255405","volume":"16","author":"YS Chen","year":"2021","unstructured":"Chen YS, Weng SJ, Chang SH et al (2021) Evaluating the anti-diabetic effects of R-verapamil in type 1 and type 2 diabetes mellitus mouse models. PLoS One 16(8):e0255405. https:\/\/doi.org\/10.1371\/journal.pone.0255405","journal-title":"PLoS One"},{"key":"6490_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2172-13-70","volume":"13","author":"CQ Xia","year":"2012","unstructured":"Xia CQ, Chernatynskaya AV, Wasserfall CH et al (2012) Anti-thymocyte globulin (ATG) differentially depletes na\u00efve and memory T cells and permits memory-type regulatory T cells in non-obese diabetic mice. BMC Immunol 13:70. https:\/\/doi.org\/10.1186\/1471-2172-13-70","journal-title":"BMC Immunol"},{"issue":"4","key":"6490_CR39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S2213-8587(13)70065-2","volume":"1","author":"SE Gitelman","year":"2013","unstructured":"Gitelman SE, Gottlieb PA, Rigby MR et al (2013) Anti-thymocyte globulin treatment for patients with recent-onset type 1 diabetes: 12-month results of a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol 1(4):306\u2013316. https:\/\/doi.org\/10.1016\/S2213-8587(13)70065-2","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"6490_CR40","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.transproceed.2020.01.013","volume":"52","author":"JH Sim","year":"2020","unstructured":"Sim JH, Han SS, Lee DS, Kim YS, Lee H, Kim HR (2020) Analysis of immune cell repopulation after anti-thymocyte globulin administration for steroid-resistant T-cell-mediated rejection. Transplant Proc 52(3):759\u2013766. https:\/\/doi.org\/10.1016\/j.transproceed.2020.01.013","journal-title":"Transplant Proc"},{"issue":"3","key":"6490_CR41","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1600-6143.2005.00759.x","volume":"5","author":"JP Pearl","year":"2005","unstructured":"Pearl JP, Parris J, Hale DA et al (2005) Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 5(3):465\u2013474. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.00759.x","journal-title":"Am J Transplant"},{"issue":"11","key":"6490_CR42","doi-asserted-by":"publisher","first-page":"e7980","DOI":"10.1371\/journal.pone.0007980","volume":"4","author":"TM Brusko","year":"2009","unstructured":"Brusko TM, Wasserfall CH, Hulme MA, Cabrera R, Schatz D, Atkinson MA (2009) Influence of membrane CD25 stability on T lymphocyte activity: implications for immunoregulation. PLoS One 4(11):e7980. https:\/\/doi.org\/10.1371\/journal.pone.0007980","journal-title":"PLoS One"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06490-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06490-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:04:40Z","timestamp":1757498680000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06490-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,12]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["6490"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06490-8","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,12]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"We thank the KU Leuven Flow and Mass Cytometry core facility (Leuven, Belgium) and the VUB VSTA core facility (Brussels, Belgium). Some of the data were presented as an oral presentation by P-JM at the 60th Meeting of the EASD in September 2024, and as a poster presentation by P-JM at the 20th Meeting of the Immunology of Diabetes Society (IDS) in November 2024.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Data supporting the results from this study are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"This work was funded by the Innovative Medicine Initiative 2 Joint Undertaking (IMI2 JU) under grant agreement no. 115797 (INNODIA [Innovative approach towards understanding and arresting type 1 diabetes]). This Joint Undertaking received support from the European Union\u2019s Horizon 2020 research and innovation programme and EFPIA, Breakthrough T1D (formerly known as JDRF) and The Leona M. and Harry B. Helmsley Charitable Trust. This work was supported by grants from the KU Leuven C1 funding (C1\/18\/006 and C16\/24\/012) and a small research infrastructure grant (KA\/20\/077). WS holds a Research Foundation Flanders (FWO) senior clinical investigator grant (1.8064.21N) and a Breakthrough T1D Career Development Award (CDA-2024-1491-S-B).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CM serves or has served on the advisory panels for AstraZeneca, Avotres, Boehringer Ingelheim, Eli Lilly and Company, Imcyse, Insulet, Mannkind, Medtronic, Merck Sharp and Dohme Ltd, Novartis, Novo Nordisk, Pfizer, Precigen Actobio, Roche, Sandoz, Sanofi, Vertex Pharmaceuticals and Zealand Pharma. Financial compensation for these activities has been received by KU Leuven. The authors declare that there are no other relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"CG designed the study. P-JM, LD and CG wrote the initial draft of the manuscript. P-JM, LD and MV performed mouse treatments and follow-up. YH performed RNA-scope staining. GL performed histological analyses. NG developed mATG to deplete T cells in vivo, enabling precise modulation of the immune system, and provided feedback on the manuscript. NDL and WS provided the necessary expertise to interpret the histological analyses and provided critical feedback on the manuscript. All authors critically improved the manuscript. CM and CG conceptualised the research goals, acquired major funding and discussed the data. CM and CG are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors approved the final version of this manuscript.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}